Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Oesophagostomum dentatum levamisole-sensitive nicotinic acetylcholine receptor (Ode-L-nAChR) is a pentameric ligand-gated ion channel located at the neuromuscular junction of the parasitic nematode O. dentatum, commonly known as the nodular worm of pigs (Source: 1.1.2, 1.3.2). This receptor is a member of the Cys-loop superfamily and is typically composed of subunits such as UNC-38, UNC-63, UNC-29, and ACR-8 (Source: 1.1.2, 1.3.4). Its primary biological function is to mediate fast excitatory neurotransmission, which triggers muscle contraction and enables locomotion (Source: 1.1.1, 1.3.2). In veterinary medicine, the Ode-L-nAChR is a critical therapeutic target for anthelmintic drugs like levamisole and pyrantel (Source: 1.1.2, 1.3.2). These drugs act as potent agonists, causing prolonged activation of the receptor, which leads to spastic paralysis and the subsequent expulsion of the worm from the host's intestinal tract (Source: 1.3.2, 1.4.4). The receptor exhibits pharmacological diversity, with different conductance subtypes (e.g., G35) identified through electrophysiological studies (Source: 1.2.1, 1.3.2). However, the widespread use of these anthelmintics has led to the emergence of drug resistance, often characterized by changes in receptor subunit expression or composition (Source: 1.3.1, 1.4.4). Understanding the molecular structure and diversity of these receptors is essential for developing next-generation anthelmintics to overcome resistance in livestock parasites (Source: 1.1.1, 1.4.3).
Agonist; induces spastic paralysis by causing persistent depolarization of nematode muscle cells, leading to the expulsion of the parasite from the host.
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Oesophagostomum dentatum levamisole-sensitive nicotinic acetylcholine receptor (Ode-L-nAChR).